Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.

CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

2002 • 5,269 citations

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

2000 • 2,694 citations

NATURAL KILLER CELLS IN ANTIVIRAL DEFENSE: Function and Regulation by Innate Cytokines

1999 • 2,128 citations

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

2002 • 1,853 citations

IgG Fc Receptors

2001 • 1,667 citations

Immune Inhibitory Receptors

2000 • 1,283 citations

THE INTERLEUKIN-12/INTERLEUKIN-12-RECEPTOR SYSTEM: Role in Normal and Pathologic Immune Responses

1998 • 1,253 citations

Improving the efficacy of antibody-based cancer therapies

2001 • 821 citations

FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype

1997 • 760 citations

New aspects of natural-killer-cell surveillance and therapy of cancer

2002 • 713 citations

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

1999 • 653 citations

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis

2000 • 576 citations

Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity

2001 • 521 citations

Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect

2002 • 500 citations

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

2001 • 425 citations

Rituximab: Mechanism of action and resistance

2002 • 360 citations

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas

2003 • 355 citations

Human natural killer cell receptors and co‐receptors

2001 • 324 citations

Complement activation plays a key role in the side‐effects of rituximab treatment

2001 • 324 citations

Dendritic and Natural Killer Cells Cooperate in the Control/Switch of Innate Immunity

2002 • 277 citations

Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion

2000 • 222 citations

Immune evasion of tumor cells using membrane-bound complement regulatory proteins

1999 • 204 citations

Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines.

1987 • 183 citations

Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma

2002 • 173 citations

Selective Expansion and Partial Activation of Human NK Cells and NK Receptor-Positive T Cells by IL-2 and IL-15

2001 • 172 citations

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2 /neu-positive breast cancer cells

2001 • 152 citations

Mechanism of Cytotoxicity Induced by Chimeric Mouse Human Monoclonal Antibody IDEC-C2B8 in CD20-Expressing Lymphoma Cell Lines

2000 • 148 citations

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non‐Hodgkin's lymphoma

2002 • 139 citations

Triggering FCα-Receptor I (CD89) Recruits Neutrophils as Effector Cells for CD20-Directed Antibody Therapy

2000 • 118 citations

Interleukin-13 induces expression and release of interleukin-1 decoy receptor in human polymorphonuclear cells.

1994 • 86 citations

Antidisialoganglioside/granulocyte macrophage–colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcγRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis

2002 • 76 citations

Immunobiology of natural killer cells and bone marrow transplantation: merging of basic and preclinical studies

2001 • 74 citations

Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils

2002 • 64 citations

Emerging information on the use of rituximab in chronic lymphocytic leukemia

2002 • 63 citations

Therapeutic efficacy of FcγRI/CD64-directed bispecific antibodies in B-cell lymphoma

2000 • 62 citations

Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.

1998 • 60 citations

Differential Effect of Cytokine Treatment on Fcα Receptor I- and Fcγ Receptor I-Mediated Tumor Cytotoxicity by Monocyte-Derived Macrophages

2000 • 44 citations

Acquired immunodeficiency syndrome‐associated lymphomas are efficiently lysed through complement‐dependent cytotoxicity and antibody‐dependent cellular cytotoxicity by rituximab

2002 • 43 citations

Complement-dependent cellular cytotoxicity: lymphoblastoid lines that activate complement component 3 (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum.

1985 • 43 citations

Intracellular Domains of Target Antigens Influence Their Capacity to Trigger Antibody-Dependent Cell-Mediated Cytotoxicity

2002 • 26 citations

Cytokine influence on killing of fresh chronic lymphocytic leukemia cells by human leukocytes

1991 • 22 citations